To reduce the frequency and severity of SSc-RP attacks: - First line therapy: dihydropyridine-type calcium antagonists (nifedipine) or PDE-5 inhibitors - Second line therapy: intraveinous prostanoids (iloprost) - Other: fluoxetine. This evidence concerns the gene PDE5A and retinitis pigmentosa 1.